Related Experiment Video
Updated: Aug 19, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome
T J H Volman1, R J A Goris, T Hendriks
1Department of Surgery, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Objective:
To investigate the effects of pentoxifylline (PTX) administration in a murine model for the multiple-organ dysfunction syndrome (MODS).
Design And Setting:
Prospective double-blind randomized animal study in a university research laboratory.
Interventions And Measurements:
Sixty C57BL/6 mice were given an aseptic intraperitoneal injection of lipopolysaccharide followed after 6 days by zymosan (day 0) at a dose of either 0.9 or 1.0 mg/g body weight. Starting on day 0 mice were administered PTX at a dose of 80 mg/kg body weight or saline per os every 8 h. On day 17 surviving animals were killed, and their liver, lungs, spleen, and kidneys were collected.
Results:
Mortality, course of body temperature, body weight, and macroscopic lung damage were similar between zymosan-treated groups. Administration of PTX did not significantly alter survival, body temperature, body weight, or macroscopic lung damage. In addition, there were no significant differences in organ weights between mice that received PTX and mice that received PBS. Although PTX inhibited the lipopolysaccharide-induced increase in tumor necrosis factor alpha and interleukin 6 expression (but not interleukin 1beta expression) at both mRNA and protein level in a murine macrophage cell line, tumor necrosis factor alpha mRNA expression in the livers of PTX-treated mice was not significantly inhibited.
Conclusions:
The results reported here do not support the hypothesis that PTX improves outcome in zymosan-induced multiple-organ dysfunction in mice.
Insights
Pentoxifylline (PTX) did not improve outcomes in a mouse model of multiple-organ dysfunction syndrome (MODS). This study found no significant effects of PTX on survival or organ damage in zymosan-induced MODS.
Area of Science:
- Pharmacology
- Immunology
- Pathophysiology
Background:
- Multiple-organ dysfunction syndrome (MODS) is a critical condition with high mortality.
- Pentoxifylline (PTX) is a phosphodiesterase inhibitor with anti-inflammatory properties.
- Investigating PTX effects in MODS models is crucial for potential therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of pentoxifylline (PTX) in a murine model of multiple-organ dysfunction syndrome (MODS).
- To assess PTX's impact on survival, physiological parameters, and organ damage in a zymosan-induced MODS model.
Main Methods:
- A prospective, double-blind, randomized animal study was conducted.
- Sixty C57BL/6 mice were induced with MODS using lipopolysaccharide and zymosan.
- Mice received either PTX (80 mg/kg) or saline, with outcomes assessed on day 17.
Main Results:
- PTX administration did not significantly alter mortality, body temperature, body weight, or macroscopic lung damage.
- No significant differences in organ weights were observed between PTX and saline groups.
- While PTX inhibited TNF-α and IL-6 in vitro, it did not significantly reduce TNF-α mRNA in mouse livers in vivo.
Conclusions:
- The study's findings do not support the hypothesis that PTX improves outcomes in zymosan-induced MODS in mice.
- PTX did not demonstrate therapeutic benefit in this specific murine model of MODS.
- Further research may be needed to explore PTX's role in other MODS contexts or mechanisms.
